Navigation Links
Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
Date:1/3/2008

NEW YORK, Jan. 3 /PRNewswire/-- Intercept Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases, today announced the appointment of Luciano Adorini, M.D., to the newly created position of Chief Scientific Officer. Dr. Adorini brings over 20 years of experience in therapeutic research and development, recently serving as Chief Scientific Officer at BioXell (SWX: BXLN), a biopharmaceutical company which he co-founded.

Mark Pruzanski, M.D., Founder, President and CEO of Intercept Pharmaceuticals, commented, "Luciano's proven R&D leadership will be invaluable as we continue to advance our pipeline of first-in-class compounds and expand our focus beyond chronic liver diseases to other indications involving progressive organ damage that results from some combination of chronic inflammation, fibrosis and metabolic dysfunction."

During Dr. Adorini's tenure at BioXell, he was responsible for advancing a broad pipeline of products in multiple disease indications. Prior to this, he served as Associate Director of Roche Milano Ricerche, where he contributed to the development of several drugs. Earlier in his career, Dr. Adorini was research director of a unit at the Preclinical Research Center, Sandoz Pharma, Ltd., in Basel.

Dr. Adorini has authored over 240 journal articles and other scientific publications, becoming a highly cited researcher in Immunology, with a focus on immunosuppressive and immunoregulatory mechanisms in the treatment of inflammatory and autoimmune diseases. He is a board member of a number of peer-reviewed publications and is currently serving as president of the Italian Society of Immunology, Clinical Immunology and Allergology. Dr. Adorini received his M.D. degree from the Medical School of Padova University and conducted postdoctoral studies at the University of California at Los Angeles.

About Intercept Pharmaceuticals '/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... SARASOTA, Fla., Dec. 1 Expanding ...Biotechnics Inc. of Sarasota has appointed Lake Ch... ,, Lake is located near Birmingham, England. ...ia which serve the agricultural, waste water, and ... hungry and to open drain fields, and clean up ind...
(Date:12/1/2009)... Congruent Software agrees to migrate ...ject accounting clients) to Synergy Business Solut... Seattle, WA (PRWEB) December 1, 2009 --... acquired the Microsoft Dynamics SL practice of Co...gy provider. The move was necessary due to a chang...
(Date:12/1/2009)... , HARBIN, China, Dec. 1 /PRNewswire-Asia-...Sky One Medical" or "the Company") (Nasdaq: CSKI ...ny developing and producing,over-the-counter drugs...announced that the Company has engaged Guangdong M...ny ("MDK") to serve as its exclusive sales agent f...
(Date:12/1/2009)... A new clinical study presented to the...that three-dimensional (3-D) automated ultrasound ...uring an in vitro fertilization (IVF) cycle is eff...measurement of the follicles. , ...Advanced Fertility Center of Chicago has just comp...
Breaking Biology Technology:Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 2China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia 3Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 2Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 3
...SAN DIEGO, April 22 BioMed Realty Trust, Inc.,(NY...ave exercised their,over-allotment option to purch...n with BioMed,s previously announced follow-on off... company sold 6,129,000 shares of,common stock, ra...6.3,million., The underwriters for the offering a...
...RNA, microRNA Researchers Comprise One of the Main... Automated Microarray Technology, MEDFORD, Mass.,...gmbh today announced it will introduce the Geniom ...ngress, which will take place April 30-May,2 in Bo...ps of febit,s new device,will benefit from the mic...
...DUBLIN, Calif., April 22 Microchip Biotechnologie...multi-patent license,agreement with GE Healthcare ...perty portfolio supporting the development of lab-...thods for creating integrated fluidic microchip,de...inues to build our strong,intellectual property po...
Other Biology Technology:BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock 2BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock 3febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress 2febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress 3Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents 2
(Date:11/30/2009)... , CLEMSON Clemson University researchers Ron Fa...vironmental Protection Agency grant to study the s...ions located deep below the earth,s surface. , W...uels believed to be the leading cause of global wa...ost promising alternatives for reducing emissions ...
(Date:11/30/2009)... HOUSTON (Nov. 30, 2009) Scientists and engineer...icine and energy will come together Dec. 7 with l...ving oil and pumping blood. , Much like moving o...hrough the body. Both systems need clean, well-fu...ges or corrosion, to function efficiently. Both in...
(Date:11/30/2009)... Take advantage of lower early bird registration ...eoporosis congress of 2010 at http://www.iofwco-e... congress of the International Osteoporosis Founda...nd Economic Aspects of Osteoporosis and Osteoarthr...ound the world are expected to attend. The excitin...
Breaking Biology News(10 mins):Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3Accumetrics Inc Announces Distribution Channels in Israel and Cyprus 48302 1Accumetrics Inc Announces Distribution Channels in Israel and Cyprus 48302 2ThermoGenesis Announces National Institute of Health Grant 4576 1ThermoGenesis Announces National Institute of Health Grant 4576 2ThermoGenesis Announces National Institute of Health Grant 4576 3ThermoGenesis Announces National Institute of Health Grant 4576 4New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes 48295 1New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes 48295 2
...t 45,000 square kilometers worldwide--about the ar...tidal marshes support few nonaquatic vertebrate sp...o the evolution of species and subspecies that are...es and subspecies, which seem to be largely restri...them to life in a harsh environment in which seed ...
..., such as those needing cancer treatment, can free...ke up to six weeks and for some this delay of trea...female egg and surrounding somatic cells) can be p...hen removed from their normal environment. , A te...developed a three-dimensional culture system that ...
...enome Project at Penn State University, with an in...n answer to Charles Darwin,s "abominable mystery:"...nts immediately after their first appearance some ...cal methods to analyze incomplete DNA sequences fr...the researchers uncovered a previously hidden "pal...
Other Biology News:Species unique to tidal marshes face threats 2New technology addresses female fertility preservation 2Massive duplication of genes may solve Darwin's 'abominable mystery' about flowering plants 2Massive duplication of genes may solve Darwin's 'abominable mystery' about flowering plants 3Massive duplication of genes may solve Darwin's 'abominable mystery' about flowering plants 4
Rabbit Anti-Human TARDBP Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Fluorescent Standards Blue Standard from Invitrogen
Fluorescent Standards Cyan Standard from Invitrogen
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE) from Molecular Probes (Invitrogen)
Biology Products: